ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer.

ESMO Open · 2026 · PMC13332459 · PMID 42378717

Europe PMC DOI

hedged sentences

0.3700

closest p · 7.4× alpha

0.5200

boldest claim

The sentences

did not reach statistical significanceP = 0.37not close (p > 0.1)

Although a good pathologic TRG was more frequent in women (61.5% versus 38.4%) and in patients with left-sided tumors (56% versus 44.4%), these differences did not reach statistical significance ( P = 0.37 and P = 0.45, respectively).

also in 111,027 other papers

a nonsignificant trendP = 0.52not close (p > 0.1)

The NAC completion rate was 94.2%, with a nonsignificant trend toward a reduced surgical complication rate compared with controls (17.3% versus 22.1%; P = 0.52).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.